Hereditary spastic paraplegia: 2026 so far

In the months covered, a few small reports described procedures for spasticity, compared only to each person's baseline.

In the months covered, small human reports described procedures meant to reduce spasticity by changing spinal or nerve signaling. Epidural spinal cord stimulation (a device that sends electrical signals to the spinal cord) in 18 people with HSP was followed by better spasticity scores, walking tests, and quality-of-life scores at 6 months compared with pre-implant baseline, without a separate control group. In 6 children with HSP, selective dorsal rhizotomy (surgery that cuts selected nerve rootlets) was followed by sharply lower spasticity and improvements in movement and daily-life measures, with reduced brace reliance and improved pain/fatigue reported for many children and no major surgical complications noted in that series. These early designs suggest some centers can measure changes after procedures, but they do not yet show how long benefits last or how they compare with other options.

Research covered in: April 2026

In the months covered, training programs and walking supports often changed a few specific walking or balance measures.

In the months covered, several small studies suggested that structured training or mobility supports can improve certain walking or balance outcomes, while other measures stayed unchanged. A 3-week robot-assisted gait training program (with traditional therapy) was linked to better 6-minute walk distance, 10-meter walk time, balance scores, and a gross motor function measure, even though formal gait analysis did not significantly change. A small randomized pilot trial of Wii-based vestibular rehab (balance training focused on the inner ear system) improved the visual-contrast component of a fall-risk assessment, and short testing with walking sticks or a four-wheel walker increased step length while other sensor gait features were mostly unchanged or sometimes worse in immediate testing. What these results support is that short-term gains may show up on certain functional tests, but changes are not consistent across all gait measures and were not always tested against controls.

Research covered in: June 2026, August 2026

A gene-specific metabolic pathway was linked to a report in one treated child.

A subtype-specific treatment idea was reported for SPTSSA-T51I complex HSP by linking the variant to sphingolipid buildup (fat-like molecules in cells) in a mouse model and testing ways to modify that pathway. In mice, dietary serine increased sphingolipid buildup and worsened neurologic problems, while myriocin normalized sphingolipid synthesis and reversed several serine-triggered harms described in the model. The same report included one treated child who received D-cycloserine and was described as having sustained improvement in spasticity, reduced baclofen need, and lower blood NFL levels. This remains an early, gene-specific signal rather than an established treatment approach for most people with HSP, because the strongest evidence here is in mice and the human experience is a single child.

Research covered in: September 2026

In the months covered, new tests were explored, and some biomarkers looked limited over short follow-up.

In the months covered, several groups worked on ways to detect and compare change in HSP more consistently, and blood biomarkers had mixed results. A sensor-based foot-tapping measure (a device test that tracks how you tap your foot) separated 41 people with HSP from matched controls and tracked with severity, including in mild-stage disease, while another analysis showed gait stability results can shift substantially depending on calculation choices (especially how base of support is defined). For SPG4, a blood immune-cell imaging measure (dcnc) separated genetically confirmed SPG4 from controls with high accuracy in one study and was reported to be higher even in asymptomatic carriers, whereas in 40 children with HSP, plasma NFL (neurofilament light, a blood marker of nerve injury) did not clearly separate subtypes or baseline mobility; levels stayed similar over a median of 9 months in the 31 children followed over time. This mix of results means measurement options are expanding, but not every proposed blood marker or gait metric behaves consistently across settings or short follow-up.

Research covered in: February 2026, June 2026, September 2026

From January 2026 to September 2026, broader testing helped sort subtypes, but gaps in diagnosis remained.

From January 2026 to September 2026, larger cohorts and targeted methods refined how often a genetic cause is found and highlighted subtype complexity, especially in children. A Korean suspected-HSP cohort found pathogenic/likely pathogenic variants in 18% and reported that targeted next-generation sequencing panels (testing many genes at once) outperformed older Sanger sequencing, while an Iranian cohort using whole-exome sequencing (testing most protein-coding genes) reported findings in most probands, including pathogenic or likely pathogenic variants and variants of uncertain significance, while 22 people remained without a genetic diagnosis. Pediatric cohorts emphasized that similar childhood spasticity can arise from many genes, often with recessive inheritance and variable MRI findings, reinforcing why broad testing is often needed. In practical terms, these studies show genetic answers are more reachable for many families, but a substantial minority still do not get a definitive cause even with advanced testing.

Research covered in: May 2026, June 2026, July 2026